Adult ADHD: The Cost of Missing It

Featuring Gregory W. Mattingly, MD
Presented by CHADD’s Advocacy & Public Policy Committee

October 1, 2026 | 12 PM ET

ADHD doesn’t end at age 18. When adult ADHD goes undiagnosed, is misdiagnosed, or is not adequately treated, the effects can extend well beyond the individual.

To begin ADHD Awareness Month, CHADD’s Public Policy Committee invites policymakers and ADHD advocates to look beyond awareness and consider what adult ADHD means for our workplaces, families, healthcare systems, public safety, and communities.

Gregory W. Mattingly, MD, past president of the American Professional Society of ADHD and Related Disorders (APSARD), will offer an engaging, evidence-based look at adult ADHD—what it can look like, how it is accurately diagnosed, and the treatment options available, including the appropriate use of medication.

Dr. Mattingly will also examine the consequences when ADHD is missed, management is discontinued, or care is poorly managed, including increased risks related to employment and economic stability, relationships, physical and mental health, substance use, driving and injury, and involvement with the justice system.

For policymakers, these are not simply healthcare concerns. The effects of undiagnosed and inadequately treated ADHD can ripple through the workforce, families, schools, healthcare systems, public safety, and communities. They have a direction financial and social cost to their constituents and communities.

This CHADD Lunch and Learn webinar will connect the science of adult ADHD with the real-world issues facing Americans and help members of Congress, congressional staff, policymakers, public policy professionals, and ADHD advocates understand why timely access to evidence-based diagnosis and treatment matters.

The forty-minute presentation is followed by audience Q&A.

Gregory W. Mattingly, MD, is a psychiatrist, researcher, educator, and nationally recognized ADHD expert. He is an associate clinical professor of psychiatry at Washington University School of Medicine, a physician and principal investigator with Midwest Research Group, and a founding partner of St. Charles Psychiatric Associates.

Dr. Mattingly has served as principal investigator in more than 400 clinical trials, including extensive research on ADHD and other psychiatric conditions. He presents nationally and internationally on ADHD, psychopharmacology, and mental health. He serves on the Scientific Advisory Board of the World Federation of ADHD.

A graduate of Washington University School of Medicine and a Fulbright Scholar, Dr. Mattingly has spent decades in clinical practice, research, and education focused on ADHD and other mental health conditions.